We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Avexis, Inc. (delisted) | NASDAQ:AVXS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 217.83 | 9.50 | 217.96 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
By Cara Lombardo
ACQUIRER: Switzerland-based Novartis AG (NVS)
TARGET: Illinois-based AveXis Inc. (AVXS)
PRICE: $8.7 billion in cash. Novartis will pay AveXis shareholders $218 a share, about an 88% premium to AveXis's Friday closing price.
RATIONALE: Novartis is expanding its bet on gene therapy and hoping a promising drug AveXis is developing for therapies aimed at spinal muscular atrophy will become a blockbuster.
STATUS: Both companies' boards have unanimously approved the deal agreement.
EXPECTED CLOSE: Mid-2018.
STOCK MOVES: AveXis shares are up 77% midday Monday. Novartis shares trading in New York rose 0.9%.
Write to Cara Lombardo at cara.lombardo@wsj.com
(END) Dow Jones Newswires
April 09, 2018 11:45 ET (15:45 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AVEXIS, INC. Chart |
1 Month AVEXIS, INC. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
